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Introduction
Idiopathic intracranial hypertension is a diagnosis of exclu-
sion defined by elevated intracranial pressure in the absence 
of any evidence of mass lesions or hydrocephalus. Persistent 
headaches, nausea, vomiting, and papilledema are the char-
acteristic signs and symptoms of this condition. It is classi-
cally associated with obese females of reproductive age but 
is also known to occur in children.1 In addition to obesity, 
known causes of idiopathic intracranial hypertension 
include vitamin derangements, certain antibiotics, corticos-
teroids, and autoimmune disorders. Certain endocrine dis-
orders, namely Cushing’s disease and Addison’s disease, 
have also been associated with idiopathic intracranial 
hypertension.2
Secondary adrenal insufficiency following withdrawal of 
inhaled corticosteroids has been found to be relatively com-
mon. In a retrospective study, 20.5% of patients on inhaled 
corticosteroids were found to have failed their adrenocorti-
cotropic hormone (ACTH) stimulation test after stopping 
steroids. The association is highest with higher doses and 
duration of treatment.3 The temporal association between the 
cessation of this patient’s corticosteroids and his onset of 
headache suggests secondary adrenal insufficiency as the 
cause of his intracranial hypertension. The gradual improve-
ment in this patient’s symptoms following steroid replace-
ment further supports this. However, this improvement may 
not be solely attributed to the steroid replacement as aceta-
zolamide was also given.
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Abstract
Idiopathic intracranial hypertension is a diagnosis of exclusion defined by elevated intracranial pressure without 
mass lesions or hydrocephalus. Causes of idiopathic intracranial hypertension include obesity, vitamin derangements, 
antibiotics, corticosteroids, and autoimmune disorders. Cushing’s disease and Addison’s disease have been associated 
with idiopathic intracranial hypertension. Secondary adrenal insufficiency following withdrawal of inhaled corticosteroids 
has been found to be a relatively common phenomenon. This case describes an 11-year-old boy who was previously 
on inhaled corticosteroids for severe asthma who presented with secondary adrenal insufficiency after withdrawal 
of steroids. The adrenal insufficiency presented as idiopathic intracranial hypertension. We described the hospital 
course and process of diagnosis for this child with secondary adrenal insufficiency following withdrawal of inhaled 
corticosteroids. The association between the discontinuation of this patient’s corticosteroids and his onset of headache 
suggests secondary adrenal insufficiency as the most likely cause of his idiopathic intracranial hypertension. The gradual 
improvement in his symptoms after steroid replacement further supports this. Due to the significant prevalence of 
children using inhaled corticosteroids, it is important for clinicians to be aware of the potential for the withdrawal of 
these drugs to induce hypothalamic–pituitary–adrenal axis suppression.
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Case report
No approval from an ethical committee or institutional 
review board is necessary in our institution for documenta-
tion of a case study. Guidelines on patient consent have been 
met by obtaining written informed consent from the family.
An 11-year-old Caucasian boy with a past medical his-
tory of severe asthma diagnosed at 7 months of age was 
admitted to the pediatric service due to severe, persistent 
headaches. The headaches had been frequent and severe for 
the past 2 months, with the most significant worsening 
occurring over the 2 weeks prior to admission. The head-
aches were described as achy and bitemporal and associated 
with nausea and mild photophobia. He reported minimal 
relief with sleep. Attempts at pharmacologically treating his 
headaches as acute migraines had proved unsuccessful. 
Review of the patient’s medical records revealed chronic 
use of multiple inhaled corticosteroids for his severe asthma. 
The patient has been using a fluticasone inhaler for 5 years 
and was started on an additional steroid inhaler, beclometa-
sone dipropionate, 7 months prior to admission. The patient 
also has a history of frequent asthma exacerbations requir-
ing hospitalization and oral steroids, with the most recent 
episode occurring 3 months prior to the current admission. 
Two months prior to the current admission, the patient was 
started on a tiotropium bromide inhaler in an effort to dis-
continue use of his inhaled corticosteroids due to the moth-
er’s concern about the patient’s growth.
His brain magnetic resonance imaging showed a pineal 
cyst and Chiari type I malformation, which were incidental 
and non-contributory. A lumbar puncture was performed and 
revealed an opening pressure greater than 55 cm of cerebro-
spinal fluid (CSF). CSF studies were within normal limits. 
35 mL of CSF were removed during the lumbar puncture, 
and closing pressure was recorded to be 15 cm of CSF. The 
patient briefly experienced some relief of his headaches after 
the lumbar puncture, but he soon began to experience wors-
ening of the headaches on standing with associated dizziness 
and vomiting. The patient was started on acetazolamide as 
well as topiramate to help relieve the patient’s migranous 
symptoms. On ophthalmology consultation, the patient was 
also found to have mild to moderate disc edema.
On hospital day 3, the patient began to complain of new-
onset, generalized abdominal pain. Physical exam revealed 
diffuse abdominal tenderness without rebound or guarding. 
He was hemodynamically stable and heart rate and blood 
pressure were within normal limits. Initial labs, including 
electrolytes, amylase, and lipase, were found to be within 
normal limits. An abdominal computerized tomography 
(CT) was unremarkable, and an abdominal X-ray revealed 
mild constipation. Adrenal insufficiency related to with-
drawal of inhaled steroids was suspected as a cause of this 
patient’s increased intracranial pressure and abdominal pain. 
Because of this suspicion, an ACTH stimulation test was 
performed and showed blunted production of cortisol. An 
8 AM cortisol level prior to cosyntropin administration was 
found to be 3.5 µg/dL. A baseline ACTH level was also 
obtained prior to the study and found to be 14.4 pg/mL. 
Cortisol levels 30 and 60 min after administration of a stand-
ard high dose (250 µg IV) of cosyntropin was administered 
were found to be 7.9 and 8.4 µg/dL, respectively. The patient 
was subsequently started on a physiologic dose of hydrocor-
tisone at 5 mg three times daily. The hydrocortisone dose was 
later increased to 10 mg three times daily due to continued 
stress from persistent vomiting.
A repeat lumbar puncture was performed 4 days after ini-
tiation of treatment and showed a markedly improved open-
ing pressure at 29.8 cm of CSF. 20 mL of CSF were removed, 
and closing pressure was recorded to be 17 cm CSF.
The patient was transferred to a higher-level facility for 
more specialized care on hospital day 6. A repeat ophthalmo-
logical examination was normal and without any evidence of 
papilledema. Both high- and low-dose cosyntropin stimula-
tion tests were repeated and found to be abnormal. He was 
started on a steroid taper after 2 days at the new facility and 
discharged home 2 days later.
Discussion
Patients with asthma have been found to have adrenal insuf-
ficiency not only with high-dose inhaled corticosteroids but 
also with low- to medium-dose inhaled corticosteroids when 
the inhaled corticosteroids have been given over a long 
period.4 One-third of patients on low- to medium-dose 
inhaled steroids for an average of 4.5 years showed adrenal 
insufficiency.5 In our case, the patient had been on high-dose 
inhaled corticosteroids for 5 years, over the maximum dose 
recommended for age. He was first on fluticasone propionate 
(Advair 230-21, two puffs twice a day). Advair is actually 
not recommended for pediatric use at all. He was then on 
another brand of fluticasone propionate (Flovent HFA 220, 
two puffs twice a day). With Flovent, the maximum dose for 
4 to 11 year olds is 176 mcg/day with the maximum dose for 
12 years and older being 1760 mcg a day. Our patient was 
receiving 880 mcg of Flovent per day. Seven months prior to 
admission beclometasone dipropionate (Qvar) 80 mcg one 
puff twice a day was also added. Qvar 80 mcg bid is the max-
imum dose for 5 to 11 year olds.
The occurrence of idiopathic intracranial hypertension 
has been reported to be associated with several endocrine 
conditions. These include primary adrenal insufficiency,6,7 
the medical or surgical treatment of Cushing’s disease,8 and 
the use of oral corticosteroids.9 However, very few cases 
have been reported describing idiopathic intracranial hyper-
tension resulting from withdrawal of inhaled corticoster-
oids.10,11 The mechanism by which adrenal insufficiency 
induces increased intracranial pressure is not currently well-
understood. It has been postulated, however, that acute corti-
costeroid withdrawal induces decreased absorption of CSF 
and increased resistance to the flow of CSF.12 Furthermore, 
Shenouda et al. 3
11β-hydroxysteroid dehydrogenase type 1, an enzyme that 
converts inactive cortisone into active cortisol, has been 
found to be expressed in the choroid plexus, supporting a 
role for cortisol in CSF volume regulation.13
Conclusion
Due to the significant prevalence of children using inhaled 
corticosteroids, it is important for clinicians to be aware of 
the potential for withdrawal of these drugs to induce hypo-
thalamic–pituitary–adrenal axis suppression. One study sug-
gests the routine performance of annual morning cortisol 
levels in asymptomatic patients chronically using inhaled 
corticosteroids as an efficient screening tool.3 Furthermore, 
it is important for clinicians to recognize idiopathic intracra-
nial hypertension as a rare presentation of adrenal insuffi-
ciency due to the damaging potential of this condition in 
causing irreversible blindness. When prescribing corticoster-
oids of any type, clinicians should carefully titrate their dos-
ages to the minimum required to achieve adequate symptom 
control.
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